Full Answer: GLP-1 agonists like semaglutide and tirzepatide primarily reduce body weight by suppressing appetite and improving insulin signaling
When you eat, your body releases the GLP-1 hormone, which signals the pancreas to release insulin and reduces the amount of sugar released by the liver
This dual mechanism is why tirzepatide consistently produces greater weight loss in clinical trials
Add the widget to you phone screen if you do get it, I love that. GLP-1 Protein, Fiber & Water Tracker FAQs Your Journey Back to You, One Day at a Time Track the plan, dose, meals, and milestones in one place that actually keeps up with your day.
Study visits took place every 2 weeks for the first month and then every 4 weeks thereafter
In WEGOVY clinical trials in adults for weight reduction, severe gastrointestinal adverse reactions were reported more frequently among patients receiving WEGOVY (4.1%) than placebo (0.9%)